No Data
No Data
Paradigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy From Bell Potter
Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%
Paradigm Biopharmaceuticals Ltd: Paradigm Receives $6.3m R&D Tax Refund
Why These Small Cap ASX Shares Could Deliver Very Big Returns in 2025
6 ASX All Ords Shares Lifted to 'Strong Buy' Consensus Ratings for the New Year
Paradigm Biopharmaceuticals Issues New Performance Rights